Hans-Harald Sedlacek

This inventor holds 38 USPTO granted patents and 1 published patent application and 3 EPO patents, primarily in Gene Therapy. Top assignees: Aventis Pharma Deutschland, Gmbh, Hoechst Aktiengesellschaft, Behringwerke Aktiengesellschaft. Active years: 1979-2012.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Hans-Harald Sedlacek. Retrieved from https://idiyas.com/inventor/hans-harald-sedlacek

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 38 (Patent Applications = 1)

% Patents Active = 89.5

EPO Patents = 3 (Patent Applications = 2)

Average Co-Inventor Count = 3.2

ph-index = 12

Forward Citations = 535(Granted Patents)

Location History:

Marburgh an der Lahn, DE (1981)
Marburg an der Lahn, DE (1982 - 1984)
Marburg, DE (1979 - 2012)

Company Filing History:

13 out of 330

Aventis Pharma Deutschland, Gmbh

patents

13 out of 6,705

Hoechst Aktiengesellschaft

patents

7 out of 340

Behringwerke Aktiengesellschaft

Hoechstaktiengesellschaft

patents

7. 1 out of 2

Sanofi-Aventis Pharma Deutschland Gmbh

patents

8. 1 out of 1

Vectron Therapeutics Ag

patent

Years Active: 1979-2012

Loading Chart...

Areas of Expertise:

Gene Therapy

Nucleic Acid Constructs

Immunomodulation

Viral Diseases

Targeted Therapies

Oncogene Control

Cell Cycle Regulation

Pharmacologically Controllable Systems

Antibody Detection

Tumor-Specific Enzymes

Active Compounds

Gene Insertion Vectors

38 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 8313751 - Compositions and methods for the prophylaxis or treatment of viral diseases (2012-11-20),

2. 7838637 - Single-chain multiple antigen-binding molecule, its preparation and use (2010-11-23),

3. 7241595 - Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates (2007-07-10),

4. 6759518 - Single-chain multiple antigen-binding molecule, its preparation and use (2004-07-06),

5. 6670147 - Nucleic acid construct for expressing active substances which can be activated by proteases, and preparation and use (2003-12-30),

6. 6610299 - Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates (2003-08-26),

7. 6576758 - Nucleic acid constructs containing hybrid promoters (2003-06-10),

8. 6495346 - Complex-forming proteins (2002-12-17),

9. 6482618 - Self-enhancing, pharmacologically controllable expression systems (2002-11-19),

10. 6475486 - Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates (2002-11-05),

11. 6465246 - Oncogene- or virus-controlled expression systems (2002-10-15),

12. 6384202 - Cell-specific active compounds regulated by the cell cycle (2002-05-07),

13. 6383785 - Self-enhancing, pharmacologically controllable expression systems (2002-05-07),

14. 6380170 - Nucleic acid construct for the cell cycle regulated expression of structural genes (2002-04-30),

15. 6358732 - DNA for expression under control of a cell cycle-dependent promoter (2002-03-19),

Title: Hans-Harald Sedlacek - The Innovative Mind from Marburg

Introduction: Hans-Harald Sedlacek is a renowned inventor hailing from Marburg, Germany, known for his groundbreaking contributions to various fields of technology and science.

Latest Patents: Sedlacek's latest patents include advancements in renewable energy technologies, medical devices, and artificial intelligence systems, showcasing his diverse range of expertise and innovative thinking.

Career Highlights: With a career spanning over two decades, Sedlacek has established himself as a pioneer in the innovation landscape, holding numerous patents and receiving recognition for his impactful inventions.

Collaborations: Throughout his career, Sedlacek has collaborated with leading research institutions, universities, and tech companies worldwide, fostering a culture of innovation and knowledge exchange.

Conclusion: Hans-Harald Sedlacek's relentless pursuit of innovation and his passion for pushing the boundaries of technology make him a true visionary in the world of inventions.

Profile summary based on public USPTO records.